+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
49.7700
1.7583
.2382
6.4341
1.9613
19.1972
High
37.1092
3.9369
No
No
No
No
No
Yes
0.0
No
No
Yes
No
Hyoscyamine, as an important natural alkaloid, is widely found in Solanaceae plants, especially in Hyoscyamus, Atropa, and Datura. Its chemical properties and biological activity give it an important position in pharmacology. With its remarkable anticholinergic effects and central nervous system regulatory functions, scopolamine has been widely studied for the treatment of various diseases, especially showing unique advantages in pain relief, antispasmodic effects, and the management of gastrointestinal diseases. In recent years, with the development of molecular pharmacology techniques, research on the mechanisms and targets of scopolamine has made significant progress, revealing its complex pharmacological network with multiple targets and pathways.
This paper aims to systematically review the chemical structure, plant origin, and extraction methods of scopolamine, provide a detailed evaluation of its pharmacological activity and mechanism of action, and, considering its medicinal properties and pharmacokinetic characteristics, explore its clinical application prospects and future research directions, providing comprehensive academic reference for researchers in the field of natural product pharmacology.
Ransoline (CAS No.: 101-31-5) is an alkaloid with a chiral center, molecular formula C17H23NO3, and molecular weight 289.3750. Its chemical core is the scopolamine backbone, which has an (S)-configuration and is often described as the conjugated base form of (S)-atropine. The structural features of this compound include an ester-linked benzene ring and a nitrogen-containing heterocycle, which impart good lipophilicity and bioactivity.
In terms of physicochemical properties, scopolamine has a LogP value of 1.7583, indicating moderate lipid solubility that facilitates crossing of cell membranes and the blood-brain barrier (BBB). Its TPSA (Topological Polar Surface Area) is 49.77 Ų, further supporting its good membrane permeability. Water solubility is 6.4341, indicating moderate solubility in the aqueous phase, facilitating formulation development. Importantly, scopolamine does not show hERG channel inhibitory activity, indicating a low risk of cardiotoxicity, and the Ames test result is 0.0, indicating no significant mutagenicity and relatively high safety.
Copolamine is mainly found in Solanaceae plants, especially abundant in the leaves, roots, and seeds of plants such as belladonna (Atropa belladonna), Hyoscyamus niger, and Datura stramonium. The content of scopolamine in plants is greatly affected by growth environment, harvest time, and plant part.
Traditional extraction methods mostly use acidic aqueous solution extraction combined with organic solvent extraction. The specific process includes:
Modern extraction technologies have gradually introduced ultrasound-assisted extraction, microwave-assisted extraction, and high-performance liquid chromatography (HPLC) separation, significantly improving extraction efficiency and purity, reducing solvent usage, and aligning with the concept of green chemistry.
The pharmacological activity of scopolamine mainly lies in its potent anticholinergic action and its ability to regulate the central nervous system. Its main pharmacological effects include:
Strabanine competitively blocks the M-type acetylcholine receptor, suppressing the excitatory response of the parasympathetic nervous system, leading to smooth muscle relaxation, reduced glandular secretion, and increased heart rate. This action gives it clinical value in treating gastrointestinal spasms, overactive bladder, and certain arrhythmias.
Research on scopolamine in analgesia is increasing, involving multiple molecular targets including TRPV1, TRPA1, CNR1 (cannabinoid receptor 1), OPRD1 (δ-opioid receptor), OPRM1 (μ-opioid receptor), OPRK1 (κ-opioid receptor), and DRD2 (dopamine D2 receptor). By modulating these targets, saperamide can influence pain transmission and perception, exerting its analgesic effect.
Straben regulates the prostaglandin synthase PTGS1 (COX-1) and PTGS2 (COX-2), participating in the regulation of inflammatory responses and reducing tissue inflammation and pain.
The effects of scopolamine on the central nervous system involve regulating the serotonin transporter SLC6A4, affecting neurotransmitter reuptake, and potentially impacting mood and cognitive function.
In summary, the multi-target pharmacological properties of scopolamine give it broad application potential in pain relief, anti-inflammation, and the treatment of neurological diseases.
The mechanism of action of scopolamine is complex, involving multiple signaling pathways and various receptor targets. The specific mechanisms are as follows:
As a classic anticholinergic drug, scopolamine competitively inhibits acetylcholine receptors in the M1-M5 subtypes, blocking parasympathetic-mediated physiological responses and relieving smooth muscle spasms and excessive secretion.
Broben regulates the TRPV1 and TRPA1 channels, two transient receptor potential channels that play key roles in pain and inflammation perception. Copolamine reduces pain signal transmission by inhibiting the activation of these channels.
Ransoline interacts δ μ with three opioid receptors (OPRM1, OPRD1, OPRK1) (OPRM1, OPRD1, OPRK1), enhancing the activity of the endogenous analgesic system and exerting analgesic and anti-anxiety effects.
The regulatory effect of scopolamine on CNR1 helps regulate neuroinflammation and pain transmission, participating in neuroprotective and analgesic mechanisms.
By regulating PTGS1 and PTGS2, scopolamine affects prostaglandin synthesis, reducing inflammatory responses and related pain.
The effect of scopolamine on SLC6A4 regulates serotonin reuptake, may improve nervous system function, and alleviate symptoms related to anxiety and depression.
The regulatory effect of scopolamine on DRD2 receptors may affect motor control and mental status, suggesting its potential application value in neuropsychiatric disorders.
In summary, sarobaline regulates the nervous system and inflammatory response through multi-target synergistic effects, forming its unique pharmacological effects.
The druggability parameters of scopolamine indicate its promising potential for drug development:
Pharmacokinetics, scopolamine is rapidly absorbed orally and has high bioavailability. In the body, it is mainly metabolized by the liver, and its metabolic products are excreted by the kidneys. Moderate half-life, supporting multiple dosing to maintain plasma concentration. The high blood-brain barrier permeability of scopolamine gives it an advantage in treating central nervous system diseases, but its potential side effects also warrant attention.
As a traditional anticholinergic drug, scopolamine has been used for many years in fields such as gastrointestinal spasms, bladder spasms, motion sickness, and Parkinson's disease. With deeper understanding of its multi-target mechanism, stenolamine demonstrates new clinical application potential in the following areas:
Based on its regulation of multiple targets such as TRPV1 and opioid receptors, scopolamine is expected to become a novel therapeutic drug for chronic pain, neuropathic pain, and inflammatory pain. Its combination therapy strategy is also worth further exploration to enhance analgesic effects and reduce side effects.
Tropole's regulation of serotonin transporter and dopamine receptors suggests its potential for adjunctive treatment in depression, anxiety, and schizophrenia. In the future, structural modification and dosage form optimization can enhance its targeting and safety.
By regulating COX enzymes and inflammatory mediators, scopolamine has the potential to be used as an adjunct therapy for inflammatory diseases, especially neuroinflammation-related conditions.
Considering the central effects and side effects of scopolamine, developing more targeted and controllable delivery systems (such as nanocarriers and sustained-release formulations) will be a key focus for future research.
By chemically modifying the scopolamine molecule, optimizing its pharmacodynamic and pharmacokinetic properties, reducing side effects, and improving selectivity, this is an important direction for promoting its clinical application.
Overall, with its unique pharmacological properties and good druggability, scopolamine has broad prospects for future applications in pain relief and the treatment of neurological diseases.
As a classic and important natural alkaloid, scopolamine holds a significant position in the field of natural product pharmacology. Its complex chemical structure, multi-target pharmacological effects, and excellent druggability make it not only effective in traditional anticholinergic therapy, but also shows new potential applications in analgesia, neuromodulation, and inflammation control. In the future, by integrating modern medicinal chemistry, molecular biology, and drug delivery technologies, research on samarine and its derivatives will be further deepened, driving its clinical translation and new drug development, and providing more innovative solutions for the treatment of related diseases. As a key source of drug discovery, the research example of scopolamine also provides valuable experience and theoretical foundation for the development of similar natural products.
Shenshuai
Wenjing
Hedandan
